News

Introduction Chronic Lymphocytic Leukemia (CLL) is the most common blood cancer in adults. It develops when there is an accumulation of atypical lymphocytes, which are a type of white blood cell in the blood, bone marrow, and lymphatic tissue. Although...

CytomX Therapeutics and Regeneron Pharmaceuticals have expanded their ongoing research collaboration focused on developing tumor-activated bispecific cancer therapy candidates, broadening the scope of an agreement that was originally established in 2019. The expanded collaboration introduces additional bispecific targets into...

Pfizer has entered into a licensing agreement with Chai Discovery, granting the pharmaceutical giant access to Chai's generative AI platform for integration into its drug discovery operations. The deal provides Pfizer with early access to the newly revealed Chai-3...

Eli Lilly has entered into a research collaboration with Ascidian Therapeutics aimed at discovering and developing treatments for kidney diseases, marking another step in the company’s ongoing genetic medicine strategy. The agreement, which could be worth up to $1.9bn for...

Sanofi has partnered with cloud data platform company Snowflake to develop an artificial intelligence-driven tool designed to assist the pharmaceutical giant's field sales representatives in their day-to-day operations. The collaboration aims to give Sanofi's field agents faster, more efficient...

Contract research, development, and manufacturing organization (CRDMO) Aragen has announced the successful production of the first commercial-scale GMP batches of Daretabart (hu1418K322A), the lead therapeutic candidate of UK-based Renaissance Pharma Limited. The milestone marks a key step forward in...

Eli Lilly has entered into a multi-program collaboration with Beijing-based Haisco Pharmaceutical Group, committing an upfront payment of $87 million and exposing itself to up to $2.97 billion in potential milestone payments. The total value of the arrangement could...